Cargando…

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds

In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simões, Eric A F, Klein, Nicola P, Sabharwal, Charu, Gurtman, Alejandra, Kitchin, Nicholas, Ukkonen, Benita, Korbal, Piotr, Zou, Jing, Xie, Xuping, Sarwar, Uzma N, Xu, Xia, Lockhart, Stephen, Cunliffe, Luke, Lu, Claire, Ma, Hua, Swanson, Kena A, Koury, Kenneth, Shi, Pei-Yong, Cooper, David, Türeci, Ӧzlem, Jansen, Kathrin U, Şahin, Uğur, Gruber, William C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146923/ https://www.ncbi.nlm.nih.gov/pubmed/36929216 http://dx.doi.org/10.1093/jpids/piad015

Ejemplares similares

Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
por: Muñoz, Flor M., et al.
Publicado: (2023)

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
por: Walter, Emmanuel B., et al.
Publicado: (2021)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Safety and Immunogenicity of the BNT162b2 Vaccine Coadministered with Seasonal Inactivated Influenza Vaccine in Adults
por: Murdoch, Louise, et al.
Publicado: (2023)

A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults
por: Haranaka, Miwa, et al.
Publicado: (2021)

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
por: Frenck, Robert W., et al.
Publicado: (2021)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

385. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2
por: Paulsen, Grant C, et al.
Publicado: (2023)

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
por: Moreira, Edson D., et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
por: Thomas, Stephen J., et al.
Publicado: (2021)

362. Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series
por: Sher, Lawrence, et al.
Publicado: (2023)

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
por: Winokur, Patricia, et al.
Publicado: (2023)

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial
por: Thomas, Stephen J., et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Characterization of zolbetuximab in pancreatic cancer models
por: Türeci, Ӧzlem, et al.
Publicado: (2018)

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
por: Muik, Alexander, et al.
Publicado: (2022)

1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine
por: Thomas, S.J., et al.
Publicado: (2021)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Shi, Pei-Yong, et al.
Publicado: (2021)

The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization
por: Zou, Jing, et al.
Publicado: (2021)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants
por: Liu, Jianying, et al.
Publicado: (2022)

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

COVID-19 Epidemiology, Immunity, and Vaccine Development in Children: A Review
por: Fergie, Jaime, et al.
Publicado: (2022)

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
por: Walsh, Edward E., et al.
Publicado: (2020)

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera
por: Xie, Xuping, et al.
Publicado: (2021)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Dangerous Liaisons: Caspase-11 and Reactive Oxygen Species Crosstalk in Pathogen Elimination
por: Roberts, JoAnn Simone, et al.
Publicado: (2015)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
por: Hui, Ai-Min, et al.
Publicado: (2022)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

BNT-162b1: Stevens-Johnson syndrome: case report
Publicado: (2021)

Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_huu7mjo88dgv0ouqh2ti0drk5d